OncoCyte set to buy Razor, reveals plans for lung cancer tests

By LabPulse.com staff writers

September 6, 2019 -- OncoCyte this week announced plans to acquire Razor Genomics and disclosed that it's aiming for a first-quarter 2020 launch of the Razor predictive test for lung cancer recurrence.

The Razor Genomics molecular prognostic assay is designed to assess risk of recurrence following the resection of early-stage, nonsquamous non-small cell lung cancer. The test received a positive initial coverage decision in August from the U.S. Centers for Medicare and Medicaid Services (CMS), which should pave the way for reimbursement.

Per the agreement, which is expected to close at the end of this month, OncoCyte is set to acquire a 25% stake in Razor for $10 million upfront, plus a $1 million milestone payment related to CMS coverage. Out of the $10 million, $4 million will go toward a prospective, randomized outcomes study of the Razor test, which is needed for inclusion in treatment guidelines, OncoCyte explained during a September 5 investor briefing. OncoCyte has an option to buy the rest of Razor for $10 million in cash plus $5 million in OncoCyte stock.

OncoCyte said the commercial launch will follow a soft launch in the fourth quarter of this year, and it expects reimbursement in the range of $3,500 to $4,000 based on rates for comparable tests. It hopes to have success similar to the Oncotype DX predictive test for breast cancer, produced by Genomic Health, which is being acquired by Exact Sciences in a recently announced deal worth $2.8 billion.

In a statement, OncoCyte noted that the deal fits with its ambition to become a comprehensive diagnostics company, with products for lung cancer patients across disease stages. OncoCyte has developed the DetermaVu noninvasive liquid biopsy test, which it is positioning as a method for providing confirmation and early diagnosis of cancer for lung nodules picked up on imaging studies. The DetermaVu platform is applicable to other types of cancer, OncoCyte noted.

Exact Sciences buys Genomic Health for $2.8B
The just-announced combination of Genomic Health and Exact Sciences will bring the Cologuard colon cancer diagnostic and Oncotype DX assay under one corporate...
TAILORx update refines use of Oncotype DX breast cancer test
Adding clinical risk factors such as tumor size and histologic grade to Oncotype DX scores for predicting cancer recurrence could help guide the treatment...
Grail to showcase liquid biopsy method at ASCO
Grail announced on May 13 that its blood test for detecting multiple cancers has breakthrough device status with the U.S. Food and Drug Administration,...
Micro-CT, blood test aid early lung cancer detection
A blood test revealed that circulating DNA levels correlated with lung tumor size on micro-CT scans of mice, indicating the blood test's potential in...
Liquid biopsy tracks response to lung cancer treatment
Two recently published studies indicate that blood-based liquid biopsy can be used to track lung cancer treatment response by measuring levels of circulating...

Copyright © 2019 LabPulse.com

Last Updated eh 9/6/2019 11:41:50 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.